Log in

OTCMKTS:COCPCocrystal Pharma Stock Price, Forecast & News

-0.04 (-2.19 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $1.79
50-Day Range
MA: $1.26
52-Week Range
Now: $1.79
Volume9.66 million shs
Average Volume4.57 million shs
Market Capitalization$93.33 million
P/E RatioN/A
Dividend YieldN/A
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:COCP



Sales & Book Value

Annual SalesN/A



Market Cap$93.33 million
Next Earnings DateN/A
OptionableNot Optionable

Receive COCP News and Ratings via Email

Sign-up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.

Cocrystal Pharma (OTCMKTS:COCP) Frequently Asked Questions

How has Cocrystal Pharma's stock been impacted by COVID-19 (Coronavirus)?

Cocrystal Pharma's stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, COCP shares have increased by 42.1% and is now trading at $1.79. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cocrystal Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cocrystal Pharma.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma Inc (OTCMKTS:COCP) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.03. The business had revenue of $0.46 million for the quarter. View Cocrystal Pharma's earnings history.

What price target have analysts set for COCP?

2 Wall Street analysts have issued twelve-month price objectives for Cocrystal Pharma's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Cocrystal Pharma's share price to reach $5.00 in the next year. This suggests a possible upside of 179.3% from the stock's current price. View analysts' price targets for Cocrystal Pharma.

Has Cocrystal Pharma been receiving favorable news coverage?

News stories about COCP stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cocrystal Pharma earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Cocrystal Pharma.

Who are some of Cocrystal Pharma's key competitors?

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Opko Health (OPK), KKR & Co Inc (KKR), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OpGen (OPGN), VBI Vaccines (VBIV), Ibio (IBIO), Vaxart (VXRT) and Gilead Sciences (GILD).

Who are Cocrystal Pharma's key executives?

Cocrystal Pharma's management team includes the following people:
  • Dr. Gary L. Wilcox, Co-Founder, Chairman & CEO (Age 73, Pay $201k)
  • Dr. Sam Lee, Co-Founder & Pres (Age 60, Pay $241k)
  • Mr. James J. Martin CPA, M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 53, Pay $231k)
  • Dr. Roger D. Kornberg, Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist & Director (Age 73)

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the OTCMKTS under the ticker symbol "COCP."

How do I buy shares of Cocrystal Pharma?

Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $1.79.

How big of a company is Cocrystal Pharma?

Cocrystal Pharma has a market capitalization of $93.33 million. Cocrystal Pharma employs 11 workers across the globe.

What is Cocrystal Pharma's official website?

The official website for Cocrystal Pharma is www.cocrystalpharma.com.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 1860 Montreal Rd, TUCKER, GA 30084-5709, United States. The company can be reached via phone at +1-425-3987178.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.